Alkermes Plc (NASDAQ:ALKS)

19.05
Delayed Data
As of Feb 26
 -0.39 / -2.01%
Today’s Change
11.98
Today|||52-Week Range
23.92
-4.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.0B

Company Description

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Contact Information

Alkermes Plc
Connaught House
Dublin Dublin 4
P:(531) 772-8000
Investor Relations:
(781) 296-8493

Employees

Shareholders

Mutual fund holders55.16%
Other institutional47.16%
Individual stakeholders1.45%

Top Executives

Richard F. PopsChairman & Chief Executive Officer
Blair C. JacksonChief Operating Officer & Executive Vice President
Iain Michael BrownSenior VP, Chief Financial & Accounting Officer
Kanchan RelwaniSenior Vice President-Medical Affairs
Craig C. HopkinsonChief Medical Officer & EVP-Research & Development